Search

Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. The article titled "Long-term outcomes of elderly patients receiving continuous flow left ventricular support" by Brozzi et al.[1] was read carefully and attentively due to its high quality and scientific contribution to the medical community. According to Topkara et al.,[4] aggressive clinical and surgical management of infections may enhance survival and reduce morbidity in patients with continuous-flow LVAD. [Extracted from the article]

Additionally, we must emphasize that the prognosis of surgical resection varies according to the histological type of the tumor, so the results cannot be generalized if the myxoma is considered the only tumor (despite being the most frequent). The article "Surgical treatment of primary cardiac tumors in the contemporary era: A single-center analysis" by Matteucci et al.1 was read with great interest. This study determined that nonmyxomatous tumors have an unfavorable prognosis; thus, it was concluded that morbidity and mortality vary depending on the cardiac tumor. [Extracted from the article]